HC Wainwright Has Optimistic Opinion of DWTX FY2026 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Equities researchers at HC Wainwright increased their FY2026 EPS estimates for Dogwood Therapeutics in a research report issued on Friday, November 6th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.78) per share for the year, up from their previous forecast of ($0.80). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.16) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at $0.55 EPS and FY2030 earnings at $1.32 EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Thursday, October 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Stock Down 6.3%

NASDAQ DWTX opened at $1.20 on Tuesday. Dogwood Therapeutics has a 1 year low of $0.90 and a 1 year high of $7.04. The business’s fifty day moving average is $1.51 and its two-hundred day moving average is $1.94.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.10 million.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.